Cantor Fitzgerald Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek maintains an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) and raises the price target from $18 to $23.
October 04, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on ALX Oncology Holdings and raised the price target from $18 to $23.
The news is directly related to ALX Oncology Holdings. The Overweight rating maintained by Cantor Fitzgerald and the increase in price target from $18 to $23 indicates a positive outlook for the company's stock. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100